Tilray's microscopic $0.7B market cap masks a company burning through credibility—it's unprofitable (hence the missing P/E), trading nowhere near its 52-week high despite a relatively neutral RSI of 43.2. With 14.16% short interest representing meaningful skepticism and the cannabis sector still facing regulatory headwinds, the stock sits in a fragile position: too small to command institutional confidence, too leveraged to macro sentiment to offer safety. The lack of earnings power combined with below-peak pricing suggests the market has already priced in significant distress, making any bounce vulnerable to reality checks rather than sustainable momentum.
Snapshot
Recent headlines
Peers in Medicinal Chemicals & Botanical Products
Build a thesis around TLRY
Type a thesis in plain English. AlgoThesis researches it with real data, cites sources, and hands back a tradeable basket.
Open in AlgoThesis →